التفاصيل البيبلوغرافية
| العنوان: |
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. |
| المؤلفون: |
Shiota, Masaki, Yokomizo, Akira, Takeuchi, Ario, Kiyoshima, Keijiro, Inokuchi, Junichi, Tatsugami, Katsunori, Naito, Seiji |
| المصدر: |
Supportive Care in Cancer; Dec2014, Vol. 22 Issue 12, p3219-3226, 8p |
| مصطلحات موضوعية: |
FEBRILE neutropenia, DOCETAXEL, CANCER chemotherapy, PROSTATE cancer patients, PROSTATE cancer treatment, QUALITY of life, LYMPHOPENIA, DISEASE risk factors |
| مستخلص: |
Purpose: Docetaxel is a standard therapy for patients with castration-resistant prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such as febrile neutropenia (FN) can impair quality of life and may become life-threatening. In this study, we clarified the AEs and risk factors associated with FN in clinical settings. Methods: This study included 37 Japanese patients with CRPC who were treated with 70-75 mg/m docetaxel and 10 mg prednisone every 3 or 4 weeks between 2008 and 2012. AEs, risk factors for FN, and the prognostic significance of several clinicopathological factors were analyzed. Results: Hematological AEs of ≥grade 3 included neutrocytopenia in 36 patients (97.3 %), leukopenia in 24 patients (64.9 %), lymphopenia in 10 patients (27.0 %), and FN in 4 patients (10.8 %). In addition, severe non-hematological AEs included colonic perforation, interstitial pneumonia, and acute respiratory distress syndrome in 1 patient each. Severe lymphopenia was positively associated with the incidence of FN. Low serum albumin and low lymphocyte count were identified as possible pre-treatment risk factors, while severe lymphopenia was identified as a post-treatment risk factor. Conclusions: Non-hematological AEs as well as substantial hematological AEs were recognized in the Japanese population treated with docetaxel chemotherapy against CRPC. Pre- and post-treatment lymphopenia and pre-treatment serum albumin should be considered in order to minimize the risk of FN when selecting patients with prostate cancer for docetaxel therapy, and when considering dose modifications, and the prophylactic use of granulocyte colony-stimulating factor. [ABSTRACT FROM AUTHOR] |
|
Copyright of Supportive Care in Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
